IDEXX Laboratories Raises FY26 Earnings and Revenue Guidance
IDEXX raised its full-year 2026 earnings and revenue guidance, citing acquisition impacts and strong CAG Diagnostics recurring revenue performance.
IDEXX raised its full-year 2026 earnings and revenue guidance, citing acquisition impacts and strong CAG Diagnostics recurring revenue performance.